LY3202626   Click here for help

GtoPdb Ligand ID: 11557

Synonyms: compound 22 [PMID: 34081466] | LY-3202626
PDB Ligand
Compound class: Synthetic organic
Comment: LY3202626 is a CNS-penetrant beta-secretase 1 (BACE1) inhibitor [2]. It was designed to mitigate ocular and liver toxicity problems that led to termination of previous clinical BACE1 inhibitor development programmes (LY2811376 and LY2886721 respectively).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 156.81
Molecular weight 498.14
XLogP 1.74
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COc1c[n]c(c[n]1)C(=O)Nc1ccc(c(c1)[C@]12N=C(N)SC[C@@H]2CN(C1)c1[n]cc(c[n]1)F)F
Isomeric SMILES COc1c[n]c(c[n]1)C(=O)Nc1ccc(c(c1)[C@]12N=C(N)SC[C@@H]2CN(C1)c1[n]cc(c[n]1)F)F
InChI InChI=1S/C22H20F2N8O2S/c1-34-18-8-26-17(7-27-18)19(33)30-14-2-3-16(24)15(4-14)22-11-32(21-28-5-13(23)6-29-21)9-12(22)10-35-20(25)31-22/h2-8,12H,9-11H2,1H3,(H2,25,31)(H,30,33)/t12-,22-/m0/s1
InChI Key VQSRKMNBWMHJKY-YTEVENLXSA-N
No information available.
Summary of Clinical Use Click here for help
Development of LY3202626 for Alzheimer's disease was terminated at Phase 2 [1].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02791191 A Study of LY3202626 on Disease Progression in Participants With Mild Alzheimer's Disease Dementia Phase 2 Interventional Eli Lilly and Company This study (NAVIGATE-AD) was terminated as it was considered unlikely that this treatment would achieve statistically significant efficacy. 1